Interleukin-2 (IL-2) (Human, Recombinant)

<strong>Human Interleukin-2 (IL-2)</strong>_x000D_ <strong>Catalog number:</strong> B2010268_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Volume/Weight:</strong> 10 ug_x000D_ <strong>pH:</strong> n/a_x000D_ <strong>Supplied as:</strong> Reconstitute before use_x000D_ <strong>Appearance:</strong> Solid_x000D_ <strong>Applications:</strong> highly pure recombinant human Interleukin 2 (IL-2, expressed in CHO cells). IL-2 is an important hematopoietic growth factor as well as an immune response modulator._x000D_ <strong>Storage:</strong> -20C_x000D_ <strong>Keywords:</strong> rHuIL-2; IL2; T-cell Growth Factor; TCGF; Aldesleukin_x000D_ <strong>Grade:</strong> Biotechnology grade. All components are highly pure (minimum 99%). All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered on a 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Marabondo S, Kaufman HL. High-dose interleukin-2 (IL-2) for the treatment of_x000D_ melanoma: safety considerations and future directions. Expert Opin Drug Saf._x000D_ 2017 Dec;16(12):1347-1357._x000D_ _x000D_ 2: Mitra S, Leonard WJ. Biology of IL-2 and its therapeutic modulation:_x000D_ Mechanisms and strategies. J Leukoc Biol. 2018 Apr;103(4):643-655._x000D_ _x000D_ 3: von Spee-Mayer C, Siegert E, Abdirama D, Rose A, Klaus A, Alexander T,_x000D_ Enghard P, Sawitzki B, Hiepe F, Radbruch A, Burmester GR, Riemekasten G, Humrich_x000D_ JY. Low-dose interleukin-2 selectively corrects regulatory T cell defects in_x000D_ patients with systemic lupus erythematosus. Ann Rheum Dis. 2016_x000D_ Jul;75(7):1407-15._x000D_ _x000D_ 4: Shao M, He J, Zhang R, Zhang X, Yang Y, Li C, Liu X, Sun X, Li Z._x000D_ Interleukin-2 Deficiency Associated with Renal Impairment in Systemic Lupus_x000D_ Erythematosus. J Interferon Cytokine Res. 2019 Feb;39(2):117-124._x000D_ _x000D_ 5: Carmenate T, Pacios A, Enamorado M, Moreno E, Garcia-Martínez K, Fuente D,_x000D_ León K. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J_x000D_ Immunol. 2013 Jun 15;190(12):6230-8._x000D_ _x000D_ 6: Grabstein K, Dower S, Gillis S, Urdal D, Larsen A. Expression of interleukin_x000D_ 2, interferon-gamma, and the IL 2 receptor by human peripheral blood_x000D_ lymphocytes. J Immunol. 1986 Jun 15;136(12):4503-8._x000D_ _x000D_ 7: Asahina Y, Komiya S, Ohagi A, Fujimoto R, Tamagaki H, Nakagawa K, Sato T,_x000D_ Akira S, Takao T, Ishii A, Nakahara Y, Hojo H. Chemical Synthesis of_x000D_ O-Glycosylated Human Interleukin-2 by the Reverse Polarity Protection Strategy._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/26012897/">Angew Chem Int Ed Engl</a>. 2015 Jul 6;54(28):8226-30._x000D_ _x000D_ <strong>Products Related to Human Interleukin-2 (IL-2)</strong>: <a href="https://moleculardepot.com/product-category/sars-cov-2/">COVID-19</a>